Bringing you essential updates from the American Heart Association (AHA) Scientific Sessions is the AHA Action Center. Here you’ll find in-depth discussions and analyses on the latest research, management guidelines, and innovations in cardiology, directly from leading experts in the field featured at the 2024 conference.
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
No benefit of routine spironolactone post-MI
No benefit of routine spironolactone post-MI
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Obicetrapib lowers LDL-c on top of other lipid-lowering therapies in HeFH
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
SBP target of lower than 120 mmHg reduces risk of CV events in T2DM
Tirzepatide reduces HF events in patients with HFpEF and obesity
Tirzepatide reduces HF events in patients with HFpEF and obesity
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
Edoxaban as alternative to warfarin after bioprosthetic valve surgery
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
DOAC does not prevent cognitive decline in adults with AF and a low risk of stroke
Acoramidis reduces all-cause mortality in ATTR-CM
Acoramidis reduces all-cause mortality in ATTR-CM
Audit and feedback strategy for pharmacists improves HF care
Audit and feedback strategy for pharmacists improves HF care
Effect of decision support system on early optimization of lipid-lowering therapy
Effect of decision support system on early optimization of lipid-lowering therapy
